Mavacoxib

Mavacoxib
Clinical data
Trade names	Trocoxil
AHFS/Drugs.com	International Drug Names
ATCvet code	QM01AH92 (WHO) ;
Legal status
Legal status	EU: Rx-only;
Identifiers
CAS Number	170569-88-7;
PubChem CID	9843089;
ChemSpider	8018804;
UNII	YFT7X7SR77;
ChEBI	CHEBI:76207;
CompTox Dashboard (EPA)	DTXSID90168880 ;
ECHA InfoCard	100.248.948
Chemical and physical data
Formula	C16H11F4N3O2S
Molar mass	385.34 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1=CC(=CC=C1C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F)F;
	InChI InChI=1S/C16H11F4N3O2S/c17-11-3-1-10(2-4-11)14-9-15(16(18,19)20)22-23(14)12-5-7-13(8-6-12)26(21,24)25/h1-9H,(H2,21,24,25); Key:TTZNQDOUNXBMJV-UHFFFAOYSA-N;

Mavacoxib (trade name Trocoxil) is a veterinary drug used to treat pain and inflammation in dogs with degenerative joint disease.^[2] It acts as a COX-2 inhibitor.^[3]

Mavacoxib, along with several other COX-2 selective inhibitors, including celecoxib, valdecoxib, and parecoxib, were discovered by a team at the Searle division of Monsanto led by John Talley.^[4]^[5]

^ "Trocoxil EPAR". European Medicines Agency. 22 September 2008. Retrieved 26 June 2024.
^ European Public Assessment Report (EPAR): Trocoxil Archived 17 March 2018 at the Wayback Machine, European Medicines Agency
^ Cox SR, Lesman SP, Boucher JF, Krautmann MJ, Hummel BD, Savides M, et al. (October 2010). "The pharmacokinetics of mavacoxib, a long-acting COX-2 inhibitor, in young adult laboratory dogs". Journal of Veterinary Pharmacology and Therapeutics. 33 (5): 461–70. doi:10.1111/j.1365-2885.2010.01165.x. PMID 20840390.{{cite journal}}: CS1 maint: overridden setting (link)
^ Langreth R (23 June 2003). "The Chemical Cobbler". Forbes.{{cite news}}: CS1 maint: overridden setting (link)
^ "Dr. John Talley: 2001 St. Louis Awardee" (PDF). Chemical Bond. 52 (5). St. Louis Section, American Chemical Society: 2. May 2001. Archived from the original (PDF) on 15 April 2018.

[1] "Trocoxil EPAR". European Medicines Agency. 22 September 2008. Retrieved 26 June 2024.

[2] European Public Assessment Report (EPAR): Trocoxil Archived 17 March 2018 at the Wayback Machine, European Medicines Agency

[3] Cox SR, Lesman SP, Boucher JF, Krautmann MJ, Hummel BD, Savides M, et al. (October 2010). "The pharmacokinetics of mavacoxib, a long-acting COX-2 inhibitor, in young adult laboratory dogs". Journal of Veterinary Pharmacology and Therapeutics. 33 (5): 461–70. doi:10.1111/j.1365-2885.2010.01165.x. PMID 20840390.{{cite journal}}: CS1 maint: overridden setting (link)

[Forbes2003-4] Langreth R (23 June 2003). "The Chemical Cobbler". Forbes.{{cite news}}: CS1 maint: overridden setting (link)

[SLACS-5] "Dr. John Talley: 2001 St. Louis Awardee" (PDF). Chemical Bond. 52 (5). St. Louis Section, American Chemical Society: 2. May 2001. Archived from the original (PDF) on 15 April 2018.

[1]

[2]

[3]

[4]

[5]